Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
Nature Medicine|March 4, 2016
The cellular origins of drug resistance in cancerGeoffrey R Oxnard
JAMA|March 4, 2008
False-positive rate of posttherapy positron emission tomography in cervical cancerGeoffrey R Oxnard
Archives of Pathology & Laboratory Medicine|October 2, 2012
Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancerGeoffrey R Oxnard
The New England Journal of Medicine|March 31, 2007
Bevacizumab for non-small-cell lung cancerGeoffrey R Oxnard
Clinical Chemistry|March 31, 2015
CommentaryGeoffrey R Oxnard
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2019
Effective Cancer Genotyping-Many Means to One EndCatherine B Meador, Geoffrey R Oxnard
Oncology (Williston Park, N.Y.)|May 20, 2010
Use of erlotinib or gefitinib as initial therapy in advanced NSCLCGeoffrey R Oxnard, Vincent A Miller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Response phenotype as a predictive biomarker to guide treatment with targeted therapiesGeoffrey R Oxnard, Lawrence H Schwartz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Does TMB Impact the Effectiveness of TKIs in <i>EGFR</i>-Mutant NSCLC?Michael L Cheng, Geoffrey R Oxnard
Hematology/Oncology Clinics of North America|December 6, 2005
The radiologic measurement of mesotheliomaSamuel G Armato, Geoffrey R Oxnard
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
Nature Medicine|March 4, 2016
The cellular origins of drug resistance in cancerGeoffrey R Oxnard
JAMA|March 4, 2008
False-positive rate of posttherapy positron emission tomography in cervical cancerGeoffrey R Oxnard
Archives of Pathology & Laboratory Medicine|October 2, 2012
Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancerGeoffrey R Oxnard
The New England Journal of Medicine|March 31, 2007
Bevacizumab for non-small-cell lung cancerGeoffrey R Oxnard
Clinical Chemistry|March 31, 2015
CommentaryGeoffrey R Oxnard
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2019
Effective Cancer Genotyping-Many Means to One EndCatherine B Meador, Geoffrey R Oxnard
Oncology (Williston Park, N.Y.)|May 20, 2010
Use of erlotinib or gefitinib as initial therapy in advanced NSCLCGeoffrey R Oxnard, Vincent A Miller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Response phenotype as a predictive biomarker to guide treatment with targeted therapiesGeoffrey R Oxnard, Lawrence H Schwartz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Does TMB Impact the Effectiveness of TKIs in <i>EGFR</i>-Mutant NSCLC?Michael L Cheng, Geoffrey R Oxnard
Hematology/Oncology Clinics of North America|December 6, 2005
The radiologic measurement of mesotheliomaSamuel G Armato, Geoffrey R Oxnard
Pageof 20